Association of endostatin D104N with leukemia

Kaohsiung Journal of Medical Sciences

Volumn 19, Issue 1, 2003, Pages 1-4

  Liu, Ta Chih ^a   Peng, Ching Tien ^b   Lin, Shen Fung ^a   Chang, Chao Sung ^a   Chen, Tyen Po ^a   Chang, Jan Gowth ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Endostatin gene; Leukemia; Polymorphism

Indexed keywords

ADENINE; ENDOSTATIN; GENOMIC DNA; GUANINE; NUCLEOTIDE; COLLAGEN; PEPTIDE FRAGMENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE FREQUENCY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; TAIWAN; GENETIC POLYMORPHISM; GENETICS;

COLLAGEN; ENDOSTATINS; HUMANS; LEUKEMIA; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC;

EID: 0037252380     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70440-1     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
3. Cline MJ. The molecular basis of leukemia. N Engl J Med 1994; 330:328-36.
4. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62.
5. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81.
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;8: 353-64.
7. Sasaki T, Fukai N, Mann K, et al. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998;17:4249-56.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
9. Cao Y. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Prog Mol Subcell Biol 1998;20:161-76.
10. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95:3403-11.
11. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85.
12. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution. EMBO J 1998;17:1656-64.
13. Dhanabal M, Ramchandran R, Waterman MJF, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274: 11721-6.
14. Muragaki Y, Timmons S, Griffin CM, et al. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement zone. Proc Natl Acad Sci USA 1995;92:8763-7.
15. Musso O, Rehn M, Theret N, et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precusor collagen XVIII in human hepatocellular carcinoma. Cancer Res 2001;61:45-9.
16. Yokohama Y, Green JE, Sukhatme VP, Ramakrishnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 2000;60:4362-5.
17. Iughetti P, Suzuki O, Godoi PHC, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001; 61:7375-8.
18. Liu TC, Lin PM, Chang JG, et al. Mutation analysis of PTEN/ MMAC1 in acute myeloid leukemia. Am J Hematol 2000; 63:170-5.
19. Chang JG, Chen PH, Chiou SS, et al. Rapid diagnosis of b-thalassemia mutations in Chinese by naturally and amplified created restriction sites. Blood 1992;80:2092-6.
20. Chang JG, Chiou SS, Perng LI, et al. Molecular characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency by natural and amplification created restriction sites: five mutations account for most G6PD deficiency cases in Taiwan. Blood 1992;80:1079-82.
21. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 2002;9:327-9.
22. Raunio H, Husgafvel-Pursianen K, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility. Gene 1995;159:113-21.
23. Rothman N, Wacholder S, Caporaso NE, et al. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 2001;1471:C1-C10.
24. Folkman J. Angiogenesis-dependent disease. Semin Oncol 2001; 28:536-42.
25. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-44.
26. Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001;3:186-96.